Leveraging its expertise in opioid antagonists, biopharmaceutical company Lightlake Therapeutics is building a platform of intranasal naloxone solutions to treat common addictions and related disorders. Lightlake has completed a phase 2 clinical trial to treat binge eating disorder and is currently developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, and has entered into a licensing deal with a subsidiary of Adapt Pharma Ltd. For more information visit the company’s website at: www.lightlaketherapeutics.com